Cargando…

Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India

BACKGROUND: Efficacy and safety are fundamental for the development of successful COVID-19 vaccines. Vaccine-associated side effects influence vaccine hesitancy. This study investigated the prevalence, severity, and onset of side effects following the first dose of COVID-19 vaccines among physicians...

Descripción completa

Detalles Bibliográficos
Autores principales: Majumder, Md Anwarul Azim, Singh, Keerti, Johnson, W M S, Rajasundaram, Archana, Gupta, Subir, Gaur, Uma, Kumar, Santosh, Chatterjee, Madhuri, Fazle Rabbi, Ahbab Mohammad, Sangishetti, Vijay Prasad, Rahman, Sayeeda, Campbell, Michael H, Harewood, Heather, Bharatha, Ambadasu, Krishnamurthy, Kandamaran, Kabir, Russell, Parsa, Ali Davod, Mohammmad, Shegufta, Haque, Mainul, Razzaque, Mohammed S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869700/
https://www.ncbi.nlm.nih.gov/pubmed/36700174
http://dx.doi.org/10.2147/JMDH.S390364
Descripción
Sumario:BACKGROUND: Efficacy and safety are fundamental for the development of successful COVID-19 vaccines. Vaccine-associated side effects influence vaccine hesitancy. This study investigated the prevalence, severity, and onset of side effects following the first dose of COVID-19 vaccines among physicians and dentists working in various healthcare settings across India. METHODS: A cross-sectional survey collected self-report data from April to June 2021 on side effects following the first dose of the vaccine. An online validated questionnaire using the Google Docs(®) platform was circulated via email and social media platforms. RESULTS: More than 40% of participants experienced at least one side effect after the first dose of vaccination; the most common were mild and resolved within three days after vaccination. More than 91% of respondents received the Covishield (AstraZeneca) vaccine; the most prevalent adverse effects were soreness of the injected arm (78.9%), tiredness (71.1%), and fever (54.9%). Logistic regression showed that women were almost 60% less likely to report side effects. CONCLUSION: Findings supported the safety of the first dose of the COVID-19 vaccine based on relatively few self-limiting side effects, mainly soreness of the injected arm and tiredness. Further research is needed to determine the long-term safety of COVID-19 vaccines, especially after booster doses.